Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia

Schmiegelow, Kjeld; Levinsen, Mette; Attarbaschi, Andishe; Baruchel, André; Devidas, Meenakshi; Escherich, Gabriele; Gibson, Brenda; Heydrich, Christiane; Horibe, Keizo; Ishida, Yasushi; Liang, Der Cherng; Locatelli, Franco; Gautier, Michel; Pieters, Rob; Piette, Caroline; Pui, Ching Hon; Raimondi, Susana C.; Silverman, Lewis B.; Stanulla, Martin; Stark, Batia; Winick, Naomi J.; Valsecchi, Maria Grazia

doi:10.1200/jco.2012.47.0500

Cited by 122 publications

(104 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diese Ergebnisse unterstreichen, dass Zweitmalignome nach kST ein großes Problem darstellen [3]. Deshalb wird von allen pädiatrischen Studiengruppen versucht, die Bestrahlungsindikation möglichst restriktiv zu stellen oder sogar völlig aufzugeben.…”

Section: Kommentarunclassified

Die Bedeutung der kraniellen Bestrahlung als Bestandteil moderner Therapieprotokolle für das Überleben bei Kindern mit akuter lymphoblastischer Leukämie

Sauer

2016

Strahlenther Onkol

View full text Add to dashboard Cite

Section: Kommentarunclassified

Die Bedeutung der kraniellen Bestrahlung als Bestandteil moderner Therapieprotokolle für das Überleben bei Kindern mit akuter lymphoblastischer Leukämie

Sauer

2016

Strahlenther Onkol

View full text Add to dashboard Cite

“…Literature data indicate that around 6 to 13% of AML cases, irrespective of age, can be designated as t-AML/MDS [10,11]. In a study on 642 children who had suffered from ALL and who developed a secondary malignancy t-AML/MDS was seen in 255 children; i.e., AML in 186, MDS in 69 children [12]. After a prolonged follow-up after being cured of their primary malignancy, an increment in incidence in secondary malignancies is noted, with a total ratio of observed versus expected cases of 6603 for MDS and 226 for AML [13].…”

Section: Review Incidencementioning

confidence: 99%

“…The number of children suffering from t-AML/MDS reported in literature is very low [12,[102][103][104][105]. Tabori et al, reported on 21children with t-AML and 2 with t-MDS.…”

Section: Prognosismentioning

confidence: 99%

“…In a study on 642 children who had suffered from ALL and later developed a secondary malignancy t-AML/MDS 5-year survival estimates for AML were 11.2% for 125 patients diagnosed before 2000 and 34.1% for 61 patients diagnosed after 2000 (P<0.001); 5-year survival estimates for MDS were 17.1% for 36 patients and 48.2% for 33 patients, respectively. Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation [12].…”

Section: Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Treatment related myeloid malignancies in childhood

Berg¹

2014

Hematol Leuk

View full text Add to dashboard Cite

Incidence of treatment related AML/MDS (t-AML/MDS) in children is extremely low. Consequently assessment of data from adults and to some extent extrapolation from adults is needed. Epipodophyllotoxin induced t-AML/MDS is more common, which is likely to be related to the shorter latency period, FAB-M4, FAB-M5, APL, balanced karyotypes, 11q23 and 21q22 anomalies, inv(16) and t(15;17) are noted more often. Duration and short interval between administrations of epipodophyllotoxins results in higher incidence of t-AML/MDS. Genetic (karyotypic) make up influence duration of remission, although the relation with overall-survival is less clear. Choice of therapy should be based on co-morbidity and the likelihood to undergo intensive therapy. The majority of children with t-AML/MDS should have a transplantation. A minority of children with t-AML with inv(16), t(8;21) and t(15;19) should be considered for chemotherapy according to de-novo protocols. Monitoring of early response criteria for detection of primary resistance is advised.

show abstract

“…secondary malignancies (9,10). Targeted therapies for ALL have the potential to be more effective and have fewer side effects than current treatments.…”

mentioning

confidence: 99%

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate

Satake

Duong

Yoshida

et al. 2016

Mol Med

View full text Add to dashboard Cite

The exponential rise in molecular and genomic data has generated a vast array of therapeutic targets. Oligonucleotide-based technologies to down regulate these molecular targets have promising therapeutic efficacy. However, there is relatively limited success in translating this into effective in vivo cancer therapeutics. The primary challenge is the lack of effective cancer cell-targeted delivery methods, particularly for a systemic disease such as leukemia. We developed a novel leukemiatargeting compound composed of a monoclonal antibody directly conjugated to an antisense oligonucleotide (ASO). Our compound uses an ASO that specifically targets the transcription factor MYC-associated factor X (MAX) dimerization protein 3 (MXD3), which was previously identified to be critical for precursor B-cell (preB) acute lymphoblastic leukemia (ALL) cell survival. The MXD3 ASO was conjugated to an anti-cluster of differentiation-22 (CD22) antibody (αCD22 Ab) that specifically targets most preB ALL. We demonstrated that the αCD22 Ab-ASO conjugate treatment showed MXD3 protein knockdown and leukemia cell apoptosis in vitro. We also demonstrated that the conjugate treatment showed cytotoxicity in normal B cells, but not in other hematopoietic cells, including hematopoietic stem cells. Furthermore, the conjugate treatment at the lowest dose tested (0.2 mg/kg Ab for 6 doses -twice a week for 3 wks) more than doubled the mouse survival time in both Reh (median survival time 20.5 versus 42.5 d, p < 0.001) and primary preB ALL (median survival time 29.3 versus 63 d, p < 0.001) xenograft models. Our conjugate that uses αCD22 Ab to target the novel molecule MXD3, which is highly expressed in preB ALL cells, appears to be a promising novel therapeutic approach.

show abstract

Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia

Abstract: SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.

Cited by 122 publications

References 43 publications

Die Bedeutung der kraniellen Bestrahlung als Bestandteil moderner Therapieprotokolle für das Überleben bei Kindern mit akuter lymphoblastischer Leukämie

Die Bedeutung der kraniellen Bestrahlung als Bestandteil moderner Therapieprotokolle für das Überleben bei Kindern mit akuter lymphoblastischer Leukämie

Treatment related myeloid malignancies in childhood

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate

Contact Info

Product

Resources

About